ARCHIVES

DCT Board Approves Phase 2/3 Studies Of LAK-IL-2

This article is from The Cancer Letter archive.

Vol. 12 No. 07 | February 14, 1986

Download PDF Visit The Full Archive

Related Articles

Nutrition RFP Canceled, Job Added To Existing Contract

April 4, 1975

Itri Pays Fine, Agrees Not to Serve As Company Officer for Five Years

April 25, 2014

FDA Plans Greater Disclosures Over Wide Range Of Activities

May 21, 2010

GAO Backs DeVita On Why advances Aren’t Producing Mortality Reduction

February 5, 1988

Lymphoseek Label Updated To Include Head and Neck SCC

June 27, 2014

In Brief: Taxol Development Is NCI ‘Emergency Priority’, Dodd To Focus ACS Effort On Breast Screening

December 7, 1990